Abstract
Background
The aim of this retrospective study was to define the clinical manifestations, pathological features and prognosis of children with membranoproliferativelike Henoch-Schönlein purpura nephritis (HSPN), representing International Study of Kidney Disease in Children (ISKDC) grade VI.
Methods
Among 245 patients with HSPN treated in our hospital between 2008 and 2010, nine patients (3.7%) were diagnosed with HSPN of ISKDC grade VI (males=5, females=4, age: 9.5±2.03 years, mean±SD). The clinical features, laboratory and pathological findings, treatment and outcome of the 9 patients were retrospectively analyzed.
Results
Of the 9 patients, 7 (78%) presented with hematuria and nephrotic syndrome, and were treated with steroids (oral prednisone or intravenous methylprednisolone pulse therapy) and immunosuppressants (oral tripterygium glycosides or intravenous cyclophosphamide pulse therapy). One (11%) patient had hematuria and nephrotic range proteinuria (>50 mg/kg per 24 hours) and was treated with oral prednisone and tripterygium glycosides. Another (11%) patient presented with hematuria and moderate proteinuria (25-50 mg/kg per 24 hours) and was treated with oral tripterygium glycoside only. Histopathological examination showed diffuse glomerular mesangial and endocapillary proliferation, mesangial interposition, double-contour formation, podocyte hypertrophy, shedding, and cytoplasmic absorption droplets. The percentages of glomeruli with small cellular crescents varied from 4%-25% in 6 of 9 patients. Follow-up for 2 to 4 years showed excellent recovery in all patients.
Conclusions
The main clinical feature of ISKDC grade VI HSPN in children is a nephrotic syndrome with hematuria. The excellent prognosis of the disease was probably related to early diagnosis and treatment with steroids and/or immunosuppressants, and mild degree of glomerulosclerosis and tubulointerstitial damage.
References
Saulsbury FT. Henoch-Schönlein purpura in children: Report of 100 patients and review of the literature. Medicine 1999;78:395–409.
Neilsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand 1998;77:125–131.
Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr 1988;147:113–115.
Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005;90:916–920.
Yoshikawa N, White RH, Cameron AH. Prognostic signifi cance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol 1981;16:223–229.
Counahan R, Winterborn MH, White RH, Heaton JM, Meadow SR, Bluett NH, et al. Prognosis of Henoch–Schönlein nephritis in children. Br Med J 1977;2:11–14.
Hass M. Henoch-Schönlein purpura nephritis. In: Ennete JC, Olsen JL, Schwartz MM, Silva FG, eds. Heptinstall’s pathology of the kidney. Philadelphia: Lippincott Williams & Wilkins, 2007: 423–486.
Habib R, Niaudet R, Levy M. Schoenlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher CC, Brenner BM, eds. Renal pathology with clinical and functional correlations. Philadelphia: Lippincott, 1994: 472–523.
Soylemezoglu O, Ozkaya O, Ozen S, Bakkaloglu A, Dusunsel R, Peru H, et al. Henoch-Schönlein nephritis: a nationwide study. Nephron Clin Pract 2009;112:199–204.
Rai A, Nast C, Adler S. Henoch-Schönlein Purpura Nephritis. J Am Soc Nephrol 1999;10:2637–2644.
Heaton J, Turner DR, Cameron JS. Localization of glomerular "deposits" in Henoch—Schönlein nephritis. Histopathology 1977;1:93–104.
Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R. Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 1976;6:183–228.
Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classifi cation Henoch-Schönlein purpura. Arthritis Rheum 1990;33:1114–1121.
Dillon MJ, Ozen S. A new international classification of childhood vasculitis. Pediatr Nephrol 2006;21:1219–1222.
RobertsI S, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, et al. The Oxford classifi cation of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009;76:546–556.
Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, et al. The Oxford classifi cation of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 2009;76:534–545.
Andreoli SP, Bergstein JM. Treatment of severe IgA nephrology in children. Pediatr Nephrol 1989;3:248–253.
Foster BJ, Bernard C, Drummond KN, Sharma AK. Effective therapy for severe Henoch-Schönlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 2000;136:370–375.
Li LS, Zhang X, Chen GY. Clinical study of Tripterygium wifordii Hook in the treatment of nephritis. Chin J Intern Med 1981;20:216–220.
Wan Y, Sun W, Zhang H, Yan Q, Chen P, Dou C, et al. Multiglycoside of Tripterygium wilfordii Hook f. ameliorates prolonged mesangial lesions in experimental progressive glomerulonephritis. Nephron Exp Nephrol 2010;114:e7–e14.
Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, et al. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int 2010;77:974–988.
Wan YG, Zhao Q, Sun W, Zhang HL, Li M, Wei QX, et al. Contrasting dose-effects of multi-glycoside of Tripterygium wilfordii HOOK. f. on glomerular inflammation and hepatic damage in two types of anti-Thy1.1 glomerulonephritis. J Pharmacol Sci 2012;118:433–446.
Assadi F. Childhood Henoch-Schönlein Nephritis: A multivariate analysis of clinical features and renal morphology at disease onset. Iran J Kidney Dis 2009;3:17–21.
Ohara S, Kawasaki Y, Matsuura H, Oikawa T, Suyama K, Hosoya M. Successful therapy with tonsillectomy for severe ISKDC grade VI Henoch-Schönlein purpura nephritis and persistent nephrotic syndrome. Clin Exp Nephrol 2011;15:749–753.
Lee KA, Ha TS. A case of hypocomplementemic Henoch-Schönlein purpura presenting features of membranoproliferative glomerulonephritis. Korean J Pediatr 2005;48:81–84.
Schlöndorff D, Banas B. The mesangial cell revisited: No cell is an island. J Am Soc Nephrol 2009;20:1179–1187.
Wang C, Liu X, Peng H, Tang Y, Tang H, Chen Z, et al. Mesangial cell stimulated by immunoglobin A1 from IgA nephropathy upregulate transforming growth factor beta1 synthesis in podocytes via renin-angiotensin system activation. Arch med Res 2010;41:255–260.
Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131–2147.
Patrakka J, Tryggvason K. New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 2009;5:463–468.
Kinoue K, Hattori M, Horita S, Kawaguchi H, Ito K. Crescent formation in children with Henoch-Schönlein purpura nephritis: a pathological and immunohistochemical study. Nihon Jinzo Gakkai Shi 1996;38:364–371.
Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int 2010;78:495–502.
Shenoy M, Bradbury MG, Lewis MA, Webb NJ. Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 2007;22:1717–1722.
Kawasaki Y, Suyama K, Yugeta E, Katayose M, Suzuki S, Sakuma H, et al. The incidence and severity of Henoch-Schönlein purpura nephritis over a 22-year period in Fukushima Prefecture. Int Urol Nephrol 2010;42:1023–1029.
Coppo R, Amore A, Gianoglio B, Cacace G, Picciotto G, Roccatello D, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993;21:593–602.
Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, et al. Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int 2003;64:149–159.
Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001;21:128–133.
Wan Y, Gu L, Suzuki K, Karasawa T, Fujioka Y, Han GD, et al. Multi-glycoside of Tripterygium wilfordii Hook f. ameliorates proteinuria and acute mesangial injury induced by anti-Thy1.1 monoclonal antibody. Nephron Exp Nephrol 2005;99:121–129.
Goldstein AR, White RH, Akuse R, Chantler C. Long-Term follow-up of childhood Henoch-Schönlein purpura nephritis. Lancet 1992;339:280–282.
Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 2012; 27:901–909.
Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992;20:1–17.
Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: fi nal common pathways to end-stage renal failure. Intern Med 2004;43:9–17.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, YJ., Yang, XQ., Zhai, WS. et al. Clinicopathological features and prognosis of membranoproliferative-like Henoch-Schönlein purpura nephritis in children. World J Pediatr 11, 338–345 (2015). https://doi.org/10.1007/s12519-014-0527-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12519-014-0527-4